0
0.5
1
1.5
2+
Mortality
80%
Improvement
Relative Risk
Hospitalization
53%
Hospitalization/ER
27%
primary
Bamlanivimab/e.. Webb et al. EARLY TREATMENT
Is early treatment with bamlanivimab/etesevimab beneficial for COVID-19?
Retrospective 6,015 patients in the USA
Lower hospitalization (p<0.0001) and fewer hosp./ER visits (p<0.0001)
c19early.org
Webb et al., Open Forum Infectious Dis.., Jun 2021
Favors bamlanivimab/e..
Favors control